PURPOSE: With the increased use of chemotherapy for @entity1149 ( @entity1149 ), a growing group of @entity1 can now be considered for second-line chemotherapy. However, guidelines for the second line treatment remain to be developed. The objective of this study was to evaluate the efficacy and safety of the @entity136 and @entity1206 combination therapy in @entity1 with advanced @entity1149 , pretreated with @entity3907 and @entity902 based regimens. @entity136 has already demonstrated activity in this @entity1 group, with the combination therapy having been reported to be well tolerated in previous phase I/II studies. MATERIALS AND METHODS: Forty two @entity1 with advanced @entity1149 (stages III/IV), having received prior @entity3907 and @entity902 based chemotherapy, with an ECOG performance status (PS) 0~2, and unimpaired hematopoietic and organ function, were treated with @entity1206 , 20 mg/m2, followed by @entity136 , 1, 000 mg/m2, both administered on days 1, 8 and 15, every 4 weeks. RESULTS: Out of the 42 @entity1 enrolled, 41 were evaluable for their response, and all 42 for their @entity137 . The @entity1 's characteristics were as follows; median age=60 years (42~73), median PS=1 (range 0~2), a gender ratio 31: 11 males/females, with stages IIIA, IIIB and IV in 3, 14 and 25 cases. The objective responses included a partial response (PR) 8/41 (19.5%), a stable disease 15/41 (36.6%) and a progressive disease 18/41 (43.9%). The median @entity1054 ( @entity1054 ) and survival were 4 months, ranging from 2 to 14 months, and 8 months, ranging from 2 to 17+ months, respectively. Grade 3 @entity1398 was seen in 19% of the @entity1 , and there was no grade 4 @entity1398 or episodes of @entity1398 . No grade 4 @entity882 or other grade 3/4 non-hematological @entity137 were observed. CONCLUSION: The combination of @entity136 / @entity1206 is active and well tolerated in @entity1 with advanced @entity1149 having failed prior @entity3907 / @entity902 therapy.

Phase II Study of @entity136 and @entity1206 as Second-Line Chemotherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non small cell lung cancer'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time-to progression'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']
@entity1149 :: (MESH:D002289,Disease) :: ['Non-Small Cell Lung Cancer']
